DE602006019710D1 - Magnesiumsalze von hmg-coa-reduktase-hemmern - Google Patents
Magnesiumsalze von hmg-coa-reduktase-hemmernInfo
- Publication number
- DE602006019710D1 DE602006019710D1 DE602006019710T DE602006019710T DE602006019710D1 DE 602006019710 D1 DE602006019710 D1 DE 602006019710D1 DE 602006019710 T DE602006019710 T DE 602006019710T DE 602006019710 T DE602006019710 T DE 602006019710T DE 602006019710 D1 DE602006019710 D1 DE 602006019710D1
- Authority
- DE
- Germany
- Prior art keywords
- coa reductase
- magnesium salt
- reductase inhibitors
- hmg coa
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1108DE2005 | 2005-05-03 | ||
PCT/IB2006/051396 WO2006117761A2 (en) | 2005-05-03 | 2006-05-03 | Magnesium salts of hmg-coa reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006019710D1 true DE602006019710D1 (de) | 2011-03-03 |
Family
ID=37308379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006019710T Active DE602006019710D1 (de) | 2005-05-03 | 2006-05-03 | Magnesiumsalze von hmg-coa-reduktase-hemmern |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100222405A1 (de) |
EP (2) | EP2172452A1 (de) |
AT (1) | ATE496025T1 (de) |
DE (1) | DE602006019710D1 (de) |
DK (1) | DK1879862T3 (de) |
ES (1) | ES2304911T3 (de) |
NO (1) | NO20076191L (de) |
PT (1) | PT1879862E (de) |
WO (1) | WO2006117761A2 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
CA2631549A1 (en) * | 2005-11-29 | 2007-06-07 | Biocon Limited | Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1) |
WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
WO2009063476A1 (en) * | 2007-11-16 | 2009-05-22 | Biocon Limited | A crystalline form of atorvastatin hemi magnesium salt and a process thereof |
EP2130819A3 (de) | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Kristalline Formen von Atorvastatin-Magnesium |
WO2009157005A1 (en) * | 2008-06-26 | 2009-12-30 | Biocon Limited | Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
CA2413702A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
AU2003245736A1 (en) * | 2002-02-14 | 2003-09-04 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
WO2006070248A1 (en) * | 2004-12-28 | 2006-07-06 | Ranbaxy Laboratories Limited | Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine |
WO2006084474A2 (en) * | 2005-02-10 | 2006-08-17 | Lifecycle Pharma A/S | A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor |
DK1957452T3 (da) * | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
CA2631549A1 (en) * | 2005-11-29 | 2007-06-07 | Biocon Limited | Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1) |
WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
CN101516842A (zh) * | 2006-05-11 | 2009-08-26 | 百康有限公司 | 阿托伐他汀镁晶型b4及其方法 |
EP2130819A3 (de) * | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Kristalline Formen von Atorvastatin-Magnesium |
-
2006
- 2006-05-03 EP EP08161846A patent/EP2172452A1/de not_active Withdrawn
- 2006-05-03 DE DE602006019710T patent/DE602006019710D1/de active Active
- 2006-05-03 DK DK06765662.9T patent/DK1879862T3/da active
- 2006-05-03 US US11/913,582 patent/US20100222405A1/en not_active Abandoned
- 2006-05-03 EP EP06765662A patent/EP1879862B1/de not_active Revoked
- 2006-05-03 AT AT06765662T patent/ATE496025T1/de active
- 2006-05-03 WO PCT/IB2006/051396 patent/WO2006117761A2/en active Application Filing
- 2006-05-03 PT PT06765662T patent/PT1879862E/pt unknown
- 2006-05-03 ES ES06765662T patent/ES2304911T3/es active Active
-
2007
- 2007-11-30 NO NO20076191A patent/NO20076191L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1879862B1 (de) | 2011-01-19 |
ES2304911T1 (es) | 2008-11-01 |
EP2172452A1 (de) | 2010-04-07 |
PT1879862E (pt) | 2011-04-19 |
ATE496025T1 (de) | 2011-02-15 |
WO2006117761A3 (en) | 2007-03-29 |
EP1879862A2 (de) | 2008-01-23 |
ES2304911T3 (es) | 2011-05-30 |
US20100222405A1 (en) | 2010-09-02 |
WO2006117761A2 (en) | 2006-11-09 |
DK1879862T3 (da) | 2011-05-16 |
NO20076191L (no) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006019710D1 (de) | Magnesiumsalze von hmg-coa-reduktase-hemmern | |
ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
EA201270546A1 (ru) | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ | |
WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
EA201691142A1 (ru) | Ингибиторы мек и способы их применения | |
WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
EA201270215A1 (ru) | Apaf-1 ингибиторные соединения | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
WO2007138282A3 (en) | Bi-aryl or aryl-heteroaryl substituted indoles | |
BRPI0618381A2 (pt) | processo para a preparação do hemi-sal de cálcio do ácido (3r, 5r) -7-[2-(4-fluorofenil) -5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico | |
EA200801199A1 (ru) | Ингибиторы киназы | |
EA200702674A1 (ru) | Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
EA200601608A1 (ru) | Способ производства твёрдой фармацевтической композиции | |
WO2012002741A3 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
WO2008062476A3 (en) | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
EA200601678A1 (ru) | Новые имидазолы | |
NO20043919L (no) | Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater | |
ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
GR1006879B (el) | Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων |